Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors

Clinical trial NCT06065059 · TERMINATED

Trial details

NCT number: NCT06065059
Sponsor: Tango Therapeutics, Inc.
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Breast Cancer Ovarian Cancer Pancreas Cancer Prostate Cancer BRCA1 Mutation BRCA-Mutated Ovarian Carcinoma BRCA-Associated Breast Carcinoma HRD Positive Advanced Ovarian Cancer

Start date: 2023-12-08
Primary completion: 2024-05-22
Enrollment: 7

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.